| Literature DB >> 25122198 |
Jared M Lucas1, Cynthia Heinlein1, Tom Kim1, Susana A Hernandez1, Muzdah S Malik1, Lawrence D True2, Colm Morrissey3, Eva Corey3, Bruce Montgomery4, Elahe Mostaghel5, Nigel Clegg1, Ilsa Coleman1, Christopher M Brown6, Eric L Schneider6, Charles Craik6, Julian A Simon1, Antonio Bedalov1, Peter S Nelson7.
Abstract
UNLABELLED: TMPRSS2 is an androgen-regulated cell-surface serine protease expressed predominantly in prostate epithelium. TMPRSS2 is expressed highly in localized high-grade prostate cancers and in the majority of human prostate cancer metastases. Through the generation of mouse models with a targeted deletion of Tmprss2, we demonstrate that the activity of this protease regulates cancer cell invasion and metastasis to distant organs. By screening combinatorial peptide libraries, we identified a spectrum of TMPRSS2 substrates that include pro-hepatocyte growth factor (HGF). HGF activated by TMPRSS2 promoted c-MET receptor tyrosine kinase signaling, and initiated a proinvasive epithelial-to-mesenchymal transition phenotype. Chemical library screens identified a potent bioavailable TMPRSS2 inhibitor that suppressed prostate cancer metastasis in vivo. Together, these findings provide a mechanistic link between androgen-regulated signaling programs and prostate cancer metastasis that operate via context-dependent interactions with extracellular constituents of the tumor microenvironment. SIGNIFICANCE: The vast majority of prostate cancer deaths are due to metastasis. Loss of TMPRSS2 activity dramatically attenuated the metastatic phenotype through mechanisms involving the HGF-c-MET axis. Therapeutic approaches directed toward inhibiting TMPRSS2 may reduce the incidence or progression of metastasis in patients with prostate cancer. ©2014 American Association for Cancer Research.Entities:
Mesh:
Substances:
Year: 2014 PMID: 25122198 PMCID: PMC4409786 DOI: 10.1158/2159-8290.CD-13-1010
Source DB: PubMed Journal: Cancer Discov ISSN: 2159-8274 Impact factor: 39.397